Preclinical program with potential for disease modifying therapeutic
EDINBURGH, UK I January 11, 2023 I Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics that promote remyelination for the treatment of neurological diseases such as multiple sclerosis, announced today it has entered into an exclusive worldwide license agreement with UCB. The agreement grants Pheno Therapeutics access and rights to develop, manufacture and commercialize a preclinical-stage program of novel small molecules designed to promote remyelination.
“Pheno Therapeutics utilized its proprietary human phenotypic screening platform to discover novel and tractable therapeutic targets to modulate oligodendrocyte biology and promote remyelination. This license allows us to accelerate a promising drug target towards clinical development,” said Fraser Murray, PhD., Chief Executive Officer of Pheno Therapeutics. “Together with our human neurological drug development expertise, there is significant opportunity for Pheno Therapeutics to fast-track this program towards clinical proof-of-concept studies and potentially deliver transformational drugs for the treatment of demyelination diseases.”
“License agreements like this are a demonstration of the value UCB scientists and our partners are creating through strong research productivity, and we are confident that Pheno Therapeutics, with its expertise in phenotypic screening, stem cell technology and myelin biology, will develop this preclinical program to its full potential,” said Dhaval Patel, Executive Vice President and UCB’s Chief Scientific Officer.
Pheno Therapeutics will make a one-time upfront payment and will be responsible for development, manufacturing and global commercialization. UCB will receive milestones and tiered royalties on net sales. Further financial details of the agreement were not disclosed.
About the Program:
The preclinical program is a novel small molecule program designed to selectively modulate the activity of an undisclosed target that is preferentially expressed on human oligodendrocytes and is known to play a critical role in the biological pathway and process of myelination. The therapeutic program is being developed by Pheno Therapeutics under an exclusive worldwide license from UCB.
About Pheno Therapeutics:
Pheno Therapeutics is a discovery and development focused biotechnology company developing small molecule therapeutics that boost the function of human oligodendrocytes and their natural ability to promote remyelination for the treatment of neurological diseases with high unmet medical need such as multiple sclerosis (MS). MS is a devastating chronic disease with significant individual and societal impact that often manifests in young adults and is associated with a wide range of neurological symptoms which can progress to total physical and cognitive disability. Pheno Therapeutics is seeking to promote remyelination and reverse the critical demyelination aspect of MS. MS demyelination occurs when the immune system attacks and damages the myelin sheaths that insulate and nourish axons and nerve fibres in the central nervous system, leading to multifocal demyelination, axonal injury and neurodegeneration. For more information on Pheno Therapeutics, please visit https://www.phenotherapeutics.com.
SOURCE: Pheno Therapeutics
Post Views: 442
Preclinical program with potential for disease modifying therapeutic
EDINBURGH, UK I January 11, 2023 I Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics that promote remyelination for the treatment of neurological diseases such as multiple sclerosis, announced today it has entered into an exclusive worldwide license agreement with UCB. The agreement grants Pheno Therapeutics access and rights to develop, manufacture and commercialize a preclinical-stage program of novel small molecules designed to promote remyelination.
“Pheno Therapeutics utilized its proprietary human phenotypic screening platform to discover novel and tractable therapeutic targets to modulate oligodendrocyte biology and promote remyelination. This license allows us to accelerate a promising drug target towards clinical development,” said Fraser Murray, PhD., Chief Executive Officer of Pheno Therapeutics. “Together with our human neurological drug development expertise, there is significant opportunity for Pheno Therapeutics to fast-track this program towards clinical proof-of-concept studies and potentially deliver transformational drugs for the treatment of demyelination diseases.”
“License agreements like this are a demonstration of the value UCB scientists and our partners are creating through strong research productivity, and we are confident that Pheno Therapeutics, with its expertise in phenotypic screening, stem cell technology and myelin biology, will develop this preclinical program to its full potential,” said Dhaval Patel, Executive Vice President and UCB’s Chief Scientific Officer.
Pheno Therapeutics will make a one-time upfront payment and will be responsible for development, manufacturing and global commercialization. UCB will receive milestones and tiered royalties on net sales. Further financial details of the agreement were not disclosed.
About the Program:
The preclinical program is a novel small molecule program designed to selectively modulate the activity of an undisclosed target that is preferentially expressed on human oligodendrocytes and is known to play a critical role in the biological pathway and process of myelination. The therapeutic program is being developed by Pheno Therapeutics under an exclusive worldwide license from UCB.
About Pheno Therapeutics:
Pheno Therapeutics is a discovery and development focused biotechnology company developing small molecule therapeutics that boost the function of human oligodendrocytes and their natural ability to promote remyelination for the treatment of neurological diseases with high unmet medical need such as multiple sclerosis (MS). MS is a devastating chronic disease with significant individual and societal impact that often manifests in young adults and is associated with a wide range of neurological symptoms which can progress to total physical and cognitive disability. Pheno Therapeutics is seeking to promote remyelination and reverse the critical demyelination aspect of MS. MS demyelination occurs when the immune system attacks and damages the myelin sheaths that insulate and nourish axons and nerve fibres in the central nervous system, leading to multifocal demyelination, axonal injury and neurodegeneration. For more information on Pheno Therapeutics, please visit https://www.phenotherapeutics.com.
SOURCE: Pheno Therapeutics
Post Views: 442
